This review highlights the pathophysiological cross-talk between angiotensin II and insulin signaling in metabolic syndrome, suggesting a potential therapeutic role for angiotensin antagonists.
Answers are grounded in this paper and cite their sources.
No immediate practice change for metabolic syndrome; leaves open whether angiotensin antagonists improve outcomes in prospective trials.
A ctivation of the renin-angiotensin system (RAS) occurs in many cardiovascular disorders, and its modulation with angiotensin-converting enzyme (ACE) inhibitors is now established therapy for hypertension, left ventricular dysfunction, diabetic nephropathy, and atherosclerosis.More recently, angiotensin type 1 receptor blockers (ARBs) have shown similar promise. 1,2Research is currently focused on the role of the RAS in the metabolic syndrome (MetS), a disorder characterized primarily by insulin resistance that has emerged as a major risk factor for cardiovascular disease. 3ere, we review how cross talk between angiotensin II (AII) and insulin signaling contributes to the pathophysiology of the MetS and raises the potential for therapeutic use of angiotensin antagonists in its management.
No takes yet. Share an insight, caveat, or question.
Prasad et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: